INVERSAGO-PHARMA
19.5.2022 14:02:09 CEST | Business Wire | Press release
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announces the presentation of preclinical data at the 59th Congress of the European Renal Association (ERA), the largest annual nephrology meeting in Europe, currently held in Paris, France.
These data show that INV-202, the company’s lead peripheral CB1 blocker, reduced renal injury in a murine model of Streptozotocin (STZ)-induced Diabetes. More specifically, INV-202 reduced glomerular injury, renal fibrosis and injury to proximal tubular epithelial cells, and also preserved podocyte structure and function. In particular, there was a marked, dose-dependent reduction in albuminuria in this model of diabetes and associated kidney injury.
“The study showed that treatment with INV-202 reduced the progression of nephropathy in STZ-induced diabetic mice. Improvements in kidney size, function, and renal matrix remodeling, with corresponding gene expression were noted with both doses of 0.3 mg/kg and 3 mg/kg of INV-202”, said Dr. Tony Jourdan, Research Lead at the National Institute of Health and Medical Research (Inserm) U1231 Lipids, Nutrition, Cancer Research Centre, in Dijon, France.
Dr. Glenn Crater, CMO at Inversago added: “These results may hold promise for those patients with diabetic kidney disease for whom such a potential therapy could further slow and delay the occurrence of end-stage renal disease.”
Based on these supportive preclinical results, along with encouraging Phase 1 results, Inversago is looking forward to launching Phase 2 clinical development for INV-202.
About INV-202
INV-202 is a small molecule CB1 inverse agonist / antagonist being developed by Inversago for the potential treatment of several metabolic conditions, including Diabetic Nephropathy. It is specifically designed to preferentially interact with peripheral CB1 receptors located in the kidneys, gastro-intestinal tract, liver, pancreas, adipose tissues, muscles, lungs and other organs, thus aiming at a safe and effective therapeutic approach without the known liabilities of centrally-acting CB1 blockers. The peripheral CB1 blockade is a well-documented pathway, linked to many clinically meaningful metabolic benefits.
About STZ Model
In this treatment model of diabetic kidney disease, mice were allowed to develop complication of diabetes for twelve weeks after STZ injection. Then these C57BL6/J mice (8 per treatment group) were randomized to receive a daily oral dose of INV-202, 0.3 mg/kg and 3 mg/kg, or vehicle for four weeks. Five mice not treated with STZ were used as a non-diabetic control. At the end of treatment, urinary albumin to creatinine ratio (ACR), renal matrix remodeling, glomerular filtration and interstitial fibrosis were assessed in addition to glucose levels, body weight, and organ weights.
About Diabetic Nephropathy
Diabetic nephropathy (DN) occurs when diabetes causes damage to the glomeruli and proximal renal tubules that are essential to blood filtering and waste elimination. As a complication of type 1 and type 2 diabetes, diabetic nephropathy affects approximately 1 in 3 people living with diabetes in the United States. No cure exists for this indication and available medications only help slowing the progression of the disease and control related complications. Inversago believes that the development of a peripheral CB1 blockade represents a promising therapeutic avenue for such a metabolic disorder.
About Inversago Pharma
Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally acting CB1 inverse agonists. Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Nephropathy (DN), Non-Alcoholic Steatohepatitis (NASH), complications from obesity, Hypertriglyceridemia (HTG), Type 1 Diabetes (T1D) and Prader-Willi Syndrome (PWS), as well as fibrotic indications like Progressive Fibrosis-Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF). For more information, visit inversago.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220519005226/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hytera Introduces PDC580 Dual-Mode Rugged Radio to Support Seamless Communication Across Critical Operations9.7.2026 09:25:00 CEST | Press release
Hytera, a leading global provider of critical communications technologies and solutions, announced the launch of the PDC580 Dual-Mode Rugged Radio, developed for organizations that continue to rely on PMR while expanding broadband communications across increasingly distributed operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708879078/en/ Built to connect LTE and PMR, the Hytera PDC580 brings dual-mode communication into one compact rugged radio. “The transition from narrowband to broadband is not an overnight replacement,” said Arthur Luo, Product Manager of Hytera Smart Terminal BU. “Many organizations will operate mixed communication environments for years to come. The PDC580 is designed to make that transition seamless, allowing teams to stay connected without changing established operational workflows.” Many frontline operations involve personnel working across different locations, departments, and network
LR Invests Over €2 Million in Quality and Growth9.7.2026 09:00:00 CEST | Press release
Global demand for innovative health products continues to grow, and with it the requirements for quality, supply reliability and production capacity. LR Health & Beauty is therefore strengthening its Ahlen headquarters with an investment of more than €2 million, laying the foundation for further growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709000261/en/ New, state-of-the-art production line in Ahlen, Germany, manufacturing LR 5in1 Beauty Elixir and LR 5in1 Men's Shot. At the heart of the investment is a new, state-of-the-art production line. LR will use it to fully consolidate the manufacturing of its successful 5-in-1 products at its Ahlen headquarters. This includes, among others, the LR 5in1 Beauty Elixir and the LR 5in1 Men’s Shot. At the same time, the new facility creates the conditions for future product innovations in modern nutritional supplement concepts. By bringing the complete production of its 5-in
Robbyant Unveils LingBot-World 2.0: Pioneering Hour-Long Real-Time Generation in World Models9.7.2026 08:52:00 CEST | Press release
Robbyant, an embodied AI company within Ant Group, today announced the open-source release of LingBot-World 2.0 (Infinity). This interactive world model significantly upgraded its world prediction and interactivity capabilities, supporting hour-long continuous generation, 720p/60fps high-definition real-time output, and richer interactive actions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708757367/en/ LingBot-World 2.0: Visual Demo of Real-Time Generation LingBot-World 2.0 also integrates a native agent mechanism, evolving generated worlds from merely watchable and controllable to "sustainably interactive and dynamically evolving", a first in the world model sector. While LingBot-World 1.0 set a benchmark with minutes-level stable generation, version 2.0 pushes the boundaries toward true infinity. The model leverages a Causal Pretraining Paradigm combined with a proprietary MoBA (Mask of Bidirectional Attention) mec
Aidoptation Receives Approval for First Fully Autonomous Driving Tests on Highways in the European Union9.7.2026 08:32:00 CEST | Press release
The Limburg-based autonomous vehicle technology company has received authorization from Belgian authorities to test fully autonomous (Level 4) driving on public highways up to the 120kph speed limit. A first milestone in the EU for testing life-saving autonomous technology in high-speed scenarios where road accidents are most severe. Aidoptation BV, the autonomous vehicle technology company headquartered at DronePort in Sint-Truiden, has received official approval from the Federal Public Service Mobility (FOD) and Transport and the Flemish Agency for Roads and Traffic (AWV) to conduct fully autonomous driving tests on public highways. The permit covers 100 km on the E313 and E314 highways in the province of Limburg, and marks the first time a Level 4 fully autonomous driving system will be tested at highway speeds on public roads in the European Union. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708112110/en/ Our car d
FIFA World Cup™ Fans Embrace Referee View as Lenovo AI Brings Viewers Closer to the Pitch9.7.2026 06:00:00 CEST | Press release
91% of fans say the new broadcast technology has made the FIFA World Cup 2026™ viewing experience more dynamic New international research from Lenovo reveals that technological advancements are fundamentally changing how fans experience the FIFA World Cup 2026™, making viewers feel closer to the action than ever before. According to a survey of football fans across Australia, Canada, India, U.K., U.S., 87% say technology is improving their viewing experience, and 84% report the close-to-action camera perspectives help them feel like they're right there on the pitch. Accelerating this unprecedented view of the game is Referee View, powered by Lenovo AI that gives viewers a first-person look at the match from the referee’s point of view. The research further found: Over three-quarters (76%) of FIFA World Cup™ viewers have seen or heard about Referee View, and 91% say the close-to-action perspective is appealing. 88% say that smooth, stable footage is an important part of viewing sports f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom